Syringe News and Research

RSS

A.P. Pharma targets resubmission of APF530 NDA in 2012

A.P. Pharma, Inc., a specialty pharmaceutical company, today provided an update on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV).

25 Apr 2011

Prism Pharmaceuticals to be acquired by Baxter

Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.

From Baxter International Inc. 20 Apr 2011

Medtronic launches MARROWMAX Bone Marrow Aspiration Needle Kit in the U.S.

Expanding its leading bone grafting portfolio, Medtronic, Inc. today announced the U.S. launch of the MARROWMAX™ Bone Marrow Aspiration Needle Kit.

20 Apr 2011

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

Biogen Idec announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event.

19 Apr 2011

Baxter enters definitive agreement to acquire Prism

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire privately-held Prism Pharmaceuticals, Inc., a specialty pharmaceutical company based in King of Prussia, PA. Prism Pharmaceuticals has developed and received U.S. Food and Drug Administration (FDA) approval for multiple presentations of NEXTERONE® (amiodarone HCl), an antiarrhythmic agent.

From Baxter International Inc. 18 Apr 2011

Cellix expands European distribution network with Tebu-bio

Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.

11 Apr 2011

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Watson Pharmaceuticals, Inc. today announced that it is initiating launch activities of Nulecit, following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application.

1 Apr 2011

Repro-Med Systems net revenue increases 30% for fiscal year ending February 28, 2011

Repro-Med Systems, Inc., dba RMS Medical Products, today announced unaudited financial results for its fiscal year ended February 28, 2011, showing increases in both domestic and international sales.

31 Mar 2011

Unilife initiates Unifill syringe production for pharmaceutical companies

Unilife Corporation today announced it has commenced initial production of the Unifill ready-to-fill syringe at its FDA-registered manufacturing facility in York, Pennsylvania.

30 Mar 2011

EDT receives European approval for XEPLION injection to treat schizophrenia

Elan Drug Technologies, the drug delivery unit of Elan Corporation, plc, today announced that the first injectable product using EDT's NanoCrystal technology has been approved by the European Commission.

9 Mar 2011

Excelsior medical's SwabFlush receives FDA 510(k) clearance

Excelsior Medical Corporation announced today that it has received FDA 510(k) clearance for SwabFlush™, its latest product for the vascular access and infection control markets.

8 Mar 2011

Mindray Medical enters agreement to acquire controlling stake of Shenke

Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today an agreement to acquire a controlling stake of Shenzhen Shenke Medical Instrument Technical Development Co. Ltd. The terms of the transaction were not disclosed as the transaction is non-material to Mindray's financial statements.

From Mindray 28 Feb 2011

First patient treated in KUR-023 pilot clinical trial to assess safety and efficacy of product candidate

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has treated the first patient in a pilot clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.

28 Feb 2011

Inexpensive drug therapy shows promise in treating premature infants with childhood blindness

A readily available, inexpensive drug therapy showed a significant benefit in treating premature infants with the worst and historically most difficult-to-treat cases of retinopathy of prematurity.

17 Feb 2011

Opinions: Polio vaccines; Alternatives to DDT, insecticides; Food price volatility; Global poverty; Foreign aid for vaccines

"No one denies" that the oral polio vaccine "has considerable merits. It's cheap to make. It's easy to administer; you don't need a trained nurse with a clean syringe [like the inactive vaccine needs], just a volunteer with a dropper. And it gives excellent immunity. ... But there are problems with the method," Wendy Orent, author of the book Plague: The Mysterious Past and Terrifying Future of the World's Most Dangerous Disease, writes in a Los Angeles Times opinion piece.

10 Feb 2011

Scientists test new dry powder measles vaccine that can be inhaled

Sustained high vaccination coverage is key to preventing deaths from measles. Despite the availability of a vaccine, measles remains an important killer of children worldwide, particularly in less-developed regions where vaccination coverage is limited. A team of researchers, led by scientists at the Johns Hopkins Bloomberg School of Public Health and the University of Colorado, developed and successfully tested a dry powder, live-attenuated measles vaccine that can be inhaled.

2 Feb 2011

Antares initiates dosing in VIBEX MTX clinical study for rheumatoid arthritis

Antares Pharma, Inc. today announced that the first patient has been dosed in a clinical study evaluating the VIBEX™ MTX product which is being developed for the treatment of rheumatoid arthritis. The clinical study will evaluate several dose strengths of VIBEX MTX delivered with a proprietary autoinjector versus conventional needle and syringe administration by a healthcare professional.

2 Feb 2011

Current prevention efforts delay but do not prevent HCV among injection drug users

A recent 20-year study of injection drug users (IDUs) in Baltimore found a significant decline in new cases of HIV infection but only a slight decline in new cases of hepatitis C virus (HCV) infection. The findings suggest that efforts to curb blood-borne transmission of these viral infections have had success but must be expanded against the highly transmissible HCV.

1 Feb 2011

Revolutions Medical: Major breakthrough in automatic retractable prefilled safety syringe technology

Revolutions Medical Corporation announces a major breakthrough in automatic retractable prefilled safety syringe technology. Building on the Company's proprietary vacuum based technology, important improvements in performance have been made that will set a new gold standard for safety in automatic prefilled syringes.

31 Jan 2011

Kaneka, Atrium Medical introduce FDA-approved Xpress-Way RX Extraction Catheter

Atrium Medical Corporation and Kaneka Corporation are proud to announce the introduction of the Xpress-Way RX Extraction Catheter. Xpress-Way RX has recently received FDA 510K clearance and is indicated for the removal of fresh, soft emboli and thrombi from vessels in the coronary and peripheral vasculature.

13 Jan 2011